Health-Related Quality of Life in Pulmonary Hypertension and Its Clinical Correlates: A Cross-Sectional Study

Reis, Abílio; Santos, Mário; Vicente, Margarida; Furtado, Inês; Cruz, Célia; Melo, Alzira; Carvalho, L.; Gonçalves, Fabienne; Sá‐Couto, Pedro; Almeida, Luís

doi:10.1155/2018/3924517

Cited by 30 publications

(33 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After completion of CAMPHOR, the results obtained in the three domains show that our attended PAH population (WHO FC I-III) experiences different levels of impairment due to disease. Our results were slightly lower than those reported by Reis et al 5 in a similar cohort of patients (69.4% in WHO FC I/II vs 63.9% in our study) and reasonably lower than those reported by McCabe et al for patients with idiopathic PAH and CTEPH) 18 . Regarding factors that could affect these results and consistent with those reported by Small et al 19 , in the three CAMPHOR domains the scores were better in those patients receiving only one drug since 65.2% of WHO FC I/II and 46.2% of WHO FC III patients in our study were undergoing monotherapy for PAH.…”

Section: Discussioncontrasting

confidence: 79%

“…These proportions were higher than those reported in the REVEAL registry 20 and previous studies with measures of HRQoL that show proportions of WHO FC III-IV near 70% 18,19,21 . The association between WHO FC and CAMPHOR scores has been well described in previous cohorts 5 . We found statistically significant differences for the WHO FC and the 'Symptoms' (p = 0.004), 'Activities' (p = 0.005) and 'Quality of life' (P = 0.02) domains of CAMPHOR, showing that PRO's are good predictors of the functional capacity.…”

Section: Discussionsupporting

confidence: 65%

“…The clinical evaluation of these patients is made using variables such as World Health Organization functional class (WHO FC), 6-minute walking distance (6MWD), N-terminal prohormone of brain natriuretic peptide (NT-proBNP), cardiac index (CI) and right atrial pressure (RAP) 3,4 . However, more than one variable is usually required because no single one provides enough diagnostic and prognostic information, also they do not provide information about the health status and quality of life (QoL) of patients 2,5 . PAH produces progressive, disabling symptoms that increase morbidity and mortality 6 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical evaluation of pulmonary arterial hypertension using patient-reported outcomes: a cross-sectional study

Amor-García¹,

Garcia²,

García-González³

et al. 2020

Preprint

View full text Add to dashboard Cite

Rationale, aims and objectives Patients with pulmonary arterial hypertension (PAH) have progressive and disabling symptoms, as well as a burden of treatments and a difficult clinical evaluation that make health-related quality of life a particularly relevant endpoint in this disease. The objective of our study was to evaluate patient-reported outcomes of patients receiving specific treatment for PAH in a tertiary hospital using a specific questionnaire (Cambridge Pulmonary Hypertension Outcome Review-CAMPHOR). Methods A cross-sectional, observational, descriptive study was conducted. It included all patients receiving specific treatment for PAH in a tertiary hospital in Madrid, Spain. The inclusion period comprised between August to December 2019. CAMPHOR questionnaires containing three domains: symptoms, activities and quality of life were completed by the patients at the pharmacy consultation. Demographic and clinical variables, including WHO Functional Class (WHO FC), PAH-specific tests and hemodynamic parameters, were recorded. Non-parametric analyses to assess relations between variables and CAMPHOR domains were performed. Results Thirty-six patients consented to participate in the study and completed the questionnaire. Median scores for symptoms, activities, and quality of life domains were 5.5 (2.5-10), 8.0 (4.5-10.5) and 3.5 (1-7.5), respectively. Statistically significant differences were found in the three domains when comparing by WHO FC, in the activities domain for 6-meters walking test and in the quality of life domain for patients who had emergency visits or hospitalizations in the last year. Conclusions The CAMPHOR questionnaire could be useful as a complementary test to achieve an integrated evaluation of PAH patients, who could complete it easily during their routine pharmacy visits.

show abstract

Section: Discussioncontrasting

confidence: 79%

Section: Discussionsupporting

confidence: 65%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical evaluation of pulmonary arterial hypertension using patient-reported outcomes: a cross-sectional study

Amor-García¹,

Garcia²,

García-González³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The quality of life in patients with untreated chronic PH is poor, usually similar to the quality of life in patients with advanced stages of pulmonary, cardiac or renal disorders [25]. In our study, patient quality of life significantly improved after completed BPA in comparison to baseline status (p < 0.001 for both EQ5D-5L score and overall health status).…”

Section: Effect Of Bpa On Quality Of Lifesupporting

confidence: 52%

Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile

Jansa

Heller

Svoboda

et al. 2020

JCM

View full text Add to dashboard Cite

Balloon pulmonary angioplasty (BPA) is a novel treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are not eligible for pulmonary endarterectomy (PEA) or suffer from persistent pulmonary hypertension after PEA. The aim of this study was to evaluate the real-life efficacy and safety of BPA in a consecutive group of patients who were diagnosed and treated in the national referral center for CTEPH in the Czech Republic. Here we report data from 160 BPA procedures performed in 64 patients. Efficacy analysis was performed in the subgroup of 25 patients who completed BPA series. Significant improvements were observed in New York Heart Association functional class (4% to 79% in I/II, p < 0.001), 6 min walking test distance (+54.3 m, p < 0.001), risk profile (15.8% to 68.5% with presence of 2/3 low risk criteria, p < 0.001), pulmonary artery mean pressure (−18%, p < 0.001), pulmonary vascular resistance (−32%, p < 0.001), stroke volume (+17%, p = 0.011) and quality of life (+37% in assessment of overall health status by a patient, p < 0.001). We observed 1 fatal periprocedural complication (1.6% of all 64 patients) and 19 BPA-related non-fatal complications (11.9% of all 160 interventions) that predominantly included hemoptysis (10.0% of all sessions). Overall survival at 12 months was 94.6%.

show abstract

“…Quality of life in patients with untreated chronic pulmonary hypertension is poor, and is usually similar to quality of life in patients with advanced stages of pulmonary, cardiac or renal disorders 12 . Using the EQ5D-5L questionnaire for quality of life evaluation, we observed significant improvements both in EQ5D-5L score and overall self-assessed health status in comparison to values at therapy initiation after 5 months of riociguat treatment.…”

Section: Discussionmentioning

confidence: 99%

The impact of riociguat on clinical parameters and quality of life in patients with chronic thromboembolic pulmonary hypertension - results of a retrospective clinical registry

Jansa¹,

Ambrož²,

Kuchař³

et al. 2021

BIOMED PAP

View full text Add to dashboard Cite

Ales Linhart a Aims. The primary objective of the registry was to assess the impact of riociguat on clinical parameters and quality of life in patients with chronic thromboembolic pulmonary hypertension (CTEPH) that was inoperable or persistent/recurrent after pulmonary endarterectomy (PEA). In contrast to randomized pivotal trials, this non-interventional registry evaluated the effectiveness and safety of riociguat in a real-world setting. Methods. Retrospective data were collected from patients' charts as recorded in routine clinical practice from the initiation of riociguat therapy up to approximately 5 months and 1 year after this initiation. Results. In total, 51 patients from a single site were enrolled. After 5 months (mean duration) of riociguat treatment, the following improvements from baseline were observed: change of distance in the 6-minute walking distance (6MWD) (P=0.066); change of score from the quality of life questionnaire (EQ5D-5L) (P=0.020), and overall self-assessment of health status (P=0.001). New York Heart Association (NYHA) class improved in 24.3% of patients. After 11.2 months (mean duration) of riociguat treatment, the following improvements from baseline were observed: change of distance in the 6MWD test (P=0.006), and overall self-assessment of health status (P=0.009). NYHA class improved in 46.4% of patients. Riociguat was well tolerated. In total, 4 patients reported side effects, with hospitalization required in one case and 2 patients who had to discontinue the treatment. Annual survival rate was 89.1%. Conclusion. Riociguat improves functional NYHA class, distance in the 6MWD test and quality of life in a real-world patient population.

show abstract

Health-Related Quality of Life in Pulmonary Hypertension and Its Clinical Correlates: A Cross-Sectional Study

Cited by 30 publications

References 33 publications

Clinical evaluation of pulmonary arterial hypertension using patient-reported outcomes: a cross-sectional study

Clinical evaluation of pulmonary arterial hypertension using patient-reported outcomes: a cross-sectional study

Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile

The impact of riociguat on clinical parameters and quality of life in patients with chronic thromboembolic pulmonary hypertension - results of a retrospective clinical registry

Contact Info

Product

Resources

About